{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:02:40Z","timestamp":1785506560503,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11523-026-01235-y","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:30:29Z","timestamp":1784129429000},"page":"569-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA"],"prefix":"10.1007","volume":"21","author":[{"given":"Matthew S.","family":"Block","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Marcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5003-0617","authenticated-orcid":false,"given":"Katrine L.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"1235_CR1","unstructured":"NCI. Cancer stat facts: melanoma of the skin. National Cancer Institute; 2026. Contract No.: March 22, 2026."},{"issue":"8","key":"1235_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463\u201382. https:\/\/doi.org\/10.1038\/nrclinonc.2017.43.","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"1235_CR3","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1503093.","journal-title":"N Engl J Med"},{"key":"1235_CR4","unstructured":"NCCN. NCCN clinical practice guidelines in oncology: melanoma: cutaneous. 2026."},{"issue":"10","key":"1235_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006947","volume":"11","author":"AC Pavlick","year":"2023","unstructured":"Pavlick AC, Ariyan CE, Buchbinder EI, Davar D, Gibney GT, Hamid O, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer. 2023;11(10):e006947. https:\/\/doi.org\/10.1136\/jitc-2023-006947.","journal-title":"J Immunother Cancer"},{"issue":"30","key":"1235_CR6","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, et al. Systemic therapy for melanoma: ASCO guideline update. J Clin Oncol. 2023;41(30):4794\u2013820. https:\/\/doi.org\/10.1200\/JCO.23.01136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1235_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000317","volume":"3","author":"KHJ Lim","year":"2018","unstructured":"Lim KHJ, Spain L, Barker C, Georgiou A, Walls G, Gore M, et al. Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. ESMO Open. 2018;3(2):e000317. https:\/\/doi.org\/10.1136\/esmoopen-2017-000317.","journal-title":"ESMO Open"},{"issue":"1","key":"1235_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"issue":"12","key":"1235_CR9","doi-asserted-by":"publisher","first-page":"e1783","DOI":"10.1093\/oncolo\/oyae248","volume":"29","author":"S Thakker","year":"2024","unstructured":"Thakker S, Belzberg M, Jang S, Al-Mondhiry J. Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatlimab. Oncologist. 2024;29(12):e1783\u20135. https:\/\/doi.org\/10.1093\/oncolo\/oyae248.","journal-title":"Oncologist"},{"issue":"1","key":"1235_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417.","journal-title":"N Engl J Med"},{"issue":"2","key":"1235_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186\u201397. https:\/\/doi.org\/10.1200\/JCO.22.01763.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1235_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Mandala M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label Phase II trial. J Clin Oncol. 2023;41(2):212\u201321. https:\/\/doi.org\/10.1200\/JCO.21.02961.","journal-title":"J Clin Oncol"},{"key":"1235_CR13","unstructured":"Symphony. Symphony Health 2026. https:\/\/www.iconplc.com\/solutions\/real-world-intelligence\/symphony-health."},{"key":"1235_CR14","unstructured":"WHO. Clinical Classifications Software (CCS) for ICD-10-PCS (beta version) 2026. http:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccs10\/ccs10.jsp."},{"key":"1235_CR15","volume-title":"CPT 2026 professional edition","author":"AMA","year":"2026","unstructured":"AMA. CPT 2026 professional edition. American Medical Association; 2026."},{"key":"1235_CR16","volume-title":"Health care common procedure coding system (HCPCS), level II coding guide","author":"CMS","year":"2026","unstructured":"CMS. Health care common procedure coding system (HCPCS), level II coding guide. Centers for Medicare & Medicaid Services (CMS); 2026."},{"key":"1235_CR17","unstructured":"FDA. National Drug Code Directory: US Food and Drug Administration, National Inst of Health; 2026. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ndc\/."},{"issue":"5","key":"1235_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s11523-025-01164-2","volume":"20","author":"CH Yiu","year":"2025","unstructured":"Yiu CH, Menzies AM, Lu CY. Real-world outcomes of pembrolizumab in advanced melanoma by age and sex: a national population-based study. Target Oncol. 2025;20(5):847\u201359. https:\/\/doi.org\/10.1007\/s11523-025-01164-2.","journal-title":"Target Oncol"},{"key":"1235_CR19","unstructured":"R Core Team. R: a language and environment for statistical computing. Version 4.0.3. Vienna, Austria: R Foundation for Statistical Computing; 2020. https:\/\/www.R-project.org\/."},{"key":"1235_CR20","unstructured":"Tableau. Tableau Desktop Professional Edition. 2024.3.1 (20243.24.1112.0850) ed2024. p. Tableau Dashboard Software."},{"issue":"4","key":"1235_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"issue":"18","key":"1235_CR22","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1210093.","journal-title":"N Engl J Med"},{"issue":"33","key":"1235_CR23","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2014.57.3535","volume":"32","author":"DB Johnson","year":"2014","unstructured":"Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014;32(33):3697\u2013704. https:\/\/doi.org\/10.1200\/JCO.2014.57.3535.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1235_CR24","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","volume":"51","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015;51(18):2792\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2015.08.022.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1235_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/cmr.0000000000000504","volume":"29","author":"S Ghate","year":"2019","unstructured":"Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Lalibert\u00e9 F, Nakasato A, et al. Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. Melanoma Res. 2019;29(3):301\u201310. https:\/\/doi.org\/10.1097\/cmr.0000000000000504.","journal-title":"Melanoma Res"},{"key":"1235_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073474","author":"M Ottaviano","year":"2021","unstructured":"Ottaviano M, Giunta EF, Tortora M, Curvietto M, Attademo L, Bosso D, et al. BRAF gene and melanoma: back to the future. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22073474.","journal-title":"Int J Mol Sci"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01235-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01235-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01235-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:15:17Z","timestamp":1785503717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01235-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01235-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"16 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by Replimune Inc.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthew S. Block receives institutional research support from Alkermes, Bristol-Myers Squibb, Genentech, Merck, nFerence, Perspective Therapeutics, Pharmacyclics, Regeneron, Sorrento, TILT Biotherapeutics, and Transgene. He is an (unpaid) consultant for Perspective Therapeutics, Sorrento Therapeutics, and TILT Biotherapeutics. Rene Marcotte is an employee of RCM Consulting, which has received consulting fees from Replimune. Ashley Stenzel was an employee of Replimune at the time of this project and may own stock or have stock options in that company. Katrine Wallace was an employee of Replimune at the time of this project and may own stock or have stock options in that company.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":3,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Database was obtained from a third party and is not publicly available. These deidentified insurer claims data are housed in a private database. Data are available from ICON, plc. Reuse and additional information are not available.","order":4,"name":"Ethics","label":"Data Availability Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthew S. Block: conceptualization, methodology, interpretation of data, writing\u2014review and editing. Katrine L. Wallace: conceptualization, methodology, formal analysis, data curation, visualization, writing\u2014original draft, writing\u2014review and editing. Ashley E. Stenzel: conceptualization, interpretation of data, writing\u2014review and editing. Rene Marcotte: data curation, methodology, project administration, writing\u2014review and editing. All authors read and approved the final manuscript.","order":6,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}